All In Biotech

BLA 761201 · Mylan Pharms INC

Semglee

Insulin Glargine-Yfgn · Injection · Insulin Analog

Last checked: Nov 20, 2026Latest source record: Nov 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jul 28, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

679

239 Phase 3, 12 recruiting

FAERS reports

22,377

19,546 serious, 2,448 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 23, 2026.

Insulin Glargine-yfgn is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use Insulin Glargine-yfgn is not recommended for the treatment of diabetic ketoacidosis. Insulin Glargine-yfgn is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 ) Limitations of Use Not recommended for the treatment of diabetic ketoacidosis. ( 1 )

Mechanism: The primary activity of insulin, including insulin glargine products, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SEMGLEE · INSULIN GLARGINE-YFGN 3ML(100UNITS/ML) · INJECTABLE, INJECTION · Prescription
  • SEMGLEE · INSULIN GLARGINE-YFGN 10ML(100UNITS/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Glargine" as an intervention, any sponsor and status, largest first.

All 679 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypoglycaemia1,741
  • blood glucose increased1,627
  • acute kidney injury1,066
  • dyspnoea1,005
  • nausea971
  • off label use957
  • hyperglycaemia952
  • drug ineffective923
  • diarrhoea919
  • vomiting856
  • fatigue828
  • condition aggravated768

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200499
2005108
200689
2007111
2008169
2009191
2010299
2011360
2012263
2013403
2014420
2015617
2016722
2017877
20182,418
20192,583
20201,570
20211,584
20221,964
20231,844
20242,236
20251,721
20261,728

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 986 on PubMed

Sponsor: Mylan Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.